Cycle cellulaire/point de contrôle

<p>6-O-Methyl-2’-O-methylinosine is a purine nucleoside analog known for its broad antitumor activity, particularly against indolent lymphoid malignancies.</p>

<p>BTO-1: Plk inhibitor effective in regulating phosphorylation.</p>

<p>Clofarabine-5'-diphosphatetrisodium (Clofarabine-DP trisodium) is the sodium salt form of Clofarabine-5'-diphosphate. As a metabolic product of Clofarabine, it results from phosphorylation by deoxycytidine kinase (dCK). Clofarabine-5'-diphosphate trisodium can undergo further phosphorylation to form Clofarabine-5'-triphosphate, demonstrating cytotoxicity in cancer cells by inhibiting DNA synthesis and repair.</p>

<p>CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.</p>

<p>2’-Deoxy-2’-fluorouridine 5’-monophosphate triethyl ammonium, a purine nucleoside analog, exhibits extensive antitumor effects against indolent lymphoid</p>

<p>DMT-5Me-dC(Bz)-CE Phosphoramidite aids in crafting LNAs for better fluorescent probes.</p>

<p>Uridine analogue with antitumor effects; inhibits DNA synthesis, induces apoptosis in lymphoid cancers.</p>

<p>16,16-dimethyl Prostaglandin A1 is a useful organic compound for research related to life sciences.</p>

<p>5’-O-DMT-N4-Ac-2’-F-dC is a modified nucleoside and can be used to synthesize DNA or RNA.</p>

<p>Odulimomab: anti-LFA-1 antibody, inhibits T cell growth, protects against ischemic injury, used in transplant rejection research.</p>

<p>NXL-101, an oral/IV antibiotic for Gram-positive bacteria like MRSA, was discontinued by Novexel in 2008.</p>

<p>PT-129 is a RPOTAC degrader that targets the G3BP1/2NTF2 domain (protein-RNA interaction site), facilitating the breakdown of intracellular stress granules. It prevents the formation of stress granules in stressed cells and deconstructs existing ones, thereby disrupting ATF4 transmission and inhibiting cancer cell proliferation. Stress granules (SGs) are membraneless cytoplasmic compartments formed under stress, which aid in the transfer of ATF4 from fibroblasts to tumor cells, promoting fibroblast-related tumor growth. G3BP1/2 serve as central proteins in the SG network, and inhibiting them may reduce the stress resilience of cancer cells within the tumor microenvironment. PT-129 consists of a target protein ligand (red part) G3BP1/2-Targeting ligand-1, an E3 ligase ligand (blue part) Thalidomide 4-fluoride, and a PROTAC linker (black part) Amino-PEG3-C2-acid; the E3 ligase ligand and linker form the complex Thalidomide-NH-PEG3-propionic acid.</p>

<p>DSPE-PEG3000-iRGD is a PEG compound comprising DSPE and the αv-integrin targeting peptide (iRGD). The iRGD peptide binds to αv-integrin and undergoes proteolytic cleavage within tumors to produce CRGDK/R, interacting with neuropilin-1. This results in tumor targeting and penetration capabilities. DSPE-PEG3000-iRGD is applicable in drug delivery.</p>

<p>Echistatin TFA: a minimal RGD protein from snake venom; inhibits platelet aggregation and bone resorption; targets αIIbβ3, αvβ3, α5β1.</p>

<p>5’-O-DMT-Bz-Rc is a modified nucleoside and can be used to synthesize DNA or RNA.</p>

<p>α-Methyl-DL-aspartic acid specifically inhibits argininosuccinate synthase (ASS), the rate-limiting enzyme in 1-citrulline-to-1-arginine recycling.</p>

<p>Nuclease S1 breaks down ssDNA and RNA, trims protruding ends of dsDNA.</p>

<p>5-(2-Hydroxyethyl)-2',3'-di-O-toluoyl-2'-deoxyuridine, a purine nucleoside analog, exhibits widespread antitumor activity specifically against indolent lymphoid</p>

<p>N7-Methylguanosine-5'-triphosphate-5'-adenosine (m7GpppA) diammonium, a dinucleotide cap analog, facilitates in vitro RNA transcription [1].</p>

<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>